Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
E M
EM
Sorkin
S P
SP
Clissold
R N
RN
Brogden
D000042:Absorption; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003326:Coronary Circulation / Q000187:drug effects; D004347:Drug Interactions; D006329:Heart Conduction System / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects; D007700:Kinetics; D009203:Myocardial Infarction / Q000188:drug therapy; D009543:Nifedipine / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D006830:Hydralazine; D009543:Nifedipine